FibroGen (FGEN) Stock Rating Upgraded by BidaskClub

FibroGen (NASDAQ:FGEN) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Other equities analysts also recently issued reports about the stock. ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Mizuho initiated coverage on shares of FibroGen in a report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price target for the company. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 price target on shares of FibroGen in a report on Thursday, September 14th. Finally, Jefferies Group reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $65.67.

FibroGen (NASDAQ FGEN) traded up $1.00 during trading hours on Thursday, reaching $45.55. 342,389 shares of the company’s stock traded hands, compared to its average volume of 625,865. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen has a 52-week low of $19.25 and a 52-week high of $60.15.

In other news, Director Gerald Lema acquired 3,500 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were bought at an average price of $46.70 per share, for a total transaction of $163,450.00. Following the completion of the purchase, the director now directly owns 3,500 shares of the company’s stock, valued at approximately $163,450. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock in a transaction on Monday, December 18th. The stock was sold at an average price of $42.80, for a total transaction of $85,600.00. Following the completion of the sale, the director now owns 22,000 shares of the company’s stock, valued at approximately $941,600. The disclosure for this sale can be found here. Insiders sold 307,710 shares of company stock worth $16,130,149 over the last three months. Corporate insiders own 13.60% of the company’s stock.

Several large investors have recently modified their holdings of the stock. SG Americas Securities LLC increased its stake in shares of FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in FibroGen by 1.7% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock valued at $939,000 after purchasing an additional 474 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in FibroGen by 15.4% during the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 696 shares during the last quarter. Tudor Investment Corp ET AL increased its stake in FibroGen by 7.1% during the second quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock valued at $391,000 after purchasing an additional 799 shares during the last quarter. Finally, Amalgamated Bank increased its stake in FibroGen by 15.0% during the third quarter. Amalgamated Bank now owns 8,423 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 1,097 shares during the last quarter. Institutional investors and hedge funds own 57.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “FibroGen (FGEN) Stock Rating Upgraded by BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/21/fibrogen-fgen-stock-rating-upgraded-by-bidaskclub.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply